IMMUNOHISTOCHEMICAL ASSAYS FOR THE EXPRESSION OF EPIDERMAL GROWTH FACTOR-SIGNALING PROTEINS IN ADENOID CYSTIC CARCINOMAS OF HUMAN SALIVARY GLANDS

타액선 선양낭성암종에서 상피성장인자 신호전달 단백의 발현에 관한 면역조직화학적 연구

  • Park, Young-Wook (Department of Oral and Maxillofacial Surgery, College of Dentistry, Kangnung National University) ;
  • Kim, Jung-Hwan (Department of Oral and Maxillofacial Surgery, College of Dentistry, Kangnung National University)
  • 박영욱 (강릉대학교 치과대학 구강악안면외과학교실) ;
  • 김정환 (강릉대학교 치과대학 구강악안면외과학교실)
  • Published : 2006.12.31

Abstract

Malignant tumors of the human salivary glands may arise from major or minor salivary glands. Adenoid cystic carcinoma (ACC) is the second most common malignant neoplasm in the salivary glands. ACC is occasionally highly aggressive tumor that readily invades adjacent tissues and metastasize to distant organs at early stages of the disease. Although ACC tends to grow slowly, treatment outcome may be poor due to wide local infiltration, perineural or intraneural spread and a propensity for hematogenous metastasis. Therefore, knowledge of cellular and molecular characteristics that influence the growth, survival and metastasis of tumor cells, is important for new treatment strategies of salivary ACC. I determined expressions of epiderma growth factor (EGF)-signaling molecules using surgical specimens of human ACCs. Protein expressions of EGF, transforming growth $factor(TGF)-{\alpha}$, EGF receptor (EGFR), phosphorylated EGFR (pEGFR), and human EGF receptor (HER)-2 were assessed in 18 cases of salivary ACC by immunohistochemical staining. Adjacent normal salivary tissues and mucosal tissues, uninvolved by the malignant tumor, served as internal controls. Most of the tumors, especially ACC with a tubulocribriform pattern, were positive for EGF signaling molecules. The overall percentages of the 18 specimens expressing EGF, $TGF-{\alpha}$, EGFR, pEGFR, and HER2 were 50, 89, 61, 61 and 83% respectively. Moreover, tumor-associated endothelial cells and infiltrating immune-related cells in the stroma of ACC, also expressed these biomarkers. Taken together, EGF-signaling molecules are actively expressed in salivary ACC. Therefore, we suggest that these biomarkers can be molecular targets for new treatment strategies of salivary tumors.

인간 타액선 선양낭성암종 조직 18례에 대한 면역조직화학적 염색을 시행하여 종물 주변의 정상 타액선 조직과 비교, 분석하여 다음과 같은 결과를 도출하였다. 1) EGF는 타액선 도관세포와 암종 조직의 50%에서 발현 되었으며, 정상 타액선 조직과 비교하여 암종 조직에서 발현이 증가되어 있지 않았다. 2) $TGF-{\alpha}$는 타액선 도관세포와 선포세포, 그리고 거의 모든 암종 조직에서 발현되었으며, 정상 타액선 조직과 비교하여 암종 조직에서 그 발현이 유의하게 증가되었다(P<0.05). 3) EGFR은 타액선 도관세포와 대부분의 암종 조직에서 발현되었으나, 발현의 강도에서 정상 타액선 조직과 암종 조직간의 차이는 없었다. 4) pEGFR은 정상 타액선 조직에서는 발현되지 않았으며, 암종 조직의 종양세포에서 그 발현이 증가되었다(P<0.05). 5) ErbB2/HER2는 타액선 도관세포와 거의 모든 암종 조직에서 발현되었으며, 정상 타액선 조직과 비교하여 암종 조직에서 그 발현이 유의하게 증가되었다 (P<0.05). 6) 검색된 인자들 중 $TGF-{\alpha}$와 ErbB2/HER2는 관사상체형 암종 조직에서와는 달리 충실형 암종 조직에서 100% 발현되어, 충실형 선양낭성암종의 증가된 악성도에 중요한 역할을 함을 암시하였다. 7) 종물 내의 종양관련 혈관내피세포에서도 위의 인자들이 모두 발현되어 종양관련 혈관내피세포는 선양낭성암종의 증식과 전이에 중요한 역할을 함을 알 수 있었다. 8) 종양 기질 내의 면역관련 세포들에서도 역시 위의 인자들이 발현되어 이들 세포들이 종양의 증식과 생존에 영향을 미칠 것이라는 추론을 가능하게 하였다. 위의 연구결과들을 종합하면 상피성장인자 신호전달계에 관여하는 인자들 중 $TGF-{\alpha}$, pEGFR, 그리고 ErbB2/HER2가 타액선 선양낭성암종에서 과발현 되었다. 따라서 이들 인자들이 타액선 선양낭성암종의 증식과 생존, 그리고 전이 과정에서 중요한 역할을 할 것이라는 추론을 가능하게 하였다. 추후 면역조직화학적 연구의 한계와 오류를 극복할 수 있는 기법으로 이들 인자들에 대한 재검색이 필요하리라 생각된다. 또한 과연 이들 인자들이 암생물학적으로 뿐만 아니라 임상적으로도 전이 및 환자 생존율과 관계된 인자로서의 가치가 있는지 평가해 보아야 할 것이다.

Keywords

References

  1. Fordice J, Kershaw C, El-Naggar A, Goepfert H : Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 125(2) : 149, 1999 https://doi.org/10.1001/archotol.125.2.149
  2. Friedman EW, Schwartz AE : Diagnosis of salivary gland tumors. Cancer 24 : 266, 1974 https://doi.org/10.1002/1097-0142(196908)24:2<266::AID-CNCR2820240209>3.0.CO;2-#
  3. Spiro RH : Salivary neoplasms, overview of a 35 year experience with 2,807 patients. Head Neck Surg 8 : 177, 1986 https://doi.org/10.1002/hed.2890080309
  4. El-Rayes BF, LoRusso PM : Targeting the epidermal growth factor receptor. Br J Cancer 91 : 418, 2004 https://doi.org/10.1038/sj.bjc.6601921
  5. Khazaie K, Schirrmacher V, Lichtner RB : EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 12 : 255, 1993 https://doi.org/10.1007/BF00665957
  6. Olayioye M, Neve R, Lane H et al : The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 : 3159, 2000 https://doi.org/10.1093/emboj/19.13.3159
  7. Bruns CJ, Solorzano CC, Harbiston MT et al : Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60 : 2926, 2000
  8. Radinsky R, Risin S, Fan D et al : Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1 : 19, 1995
  9. Salomon DS, Brandt R, Ciardiello F et al : Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 : 183, 1995 https://doi.org/10.1016/1040-8428(94)00144-I
  10. Craven RJ, Lightfoot H, Cance WG : A decade of tyrosine kinases: from gene discovery to therapeutics. Surg Oncol 12 : 39, 2003 https://doi.org/10.1016/S0960-7404(03)00004-5
  11. Xia W, Lau YK, Zhang HZ et al : Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 3 : 3, 1997
  12. Mendelsohn J, Baselga L : Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 14: 2787, 2003
  13. Somoza-Martin JM, Garcia-Garcia A, Barros-Angueira F et al : Gene expression profile in oral squamous cell carcinoma: a pilot study. J Oral Maxillofac Surg 63 : 786, 2005 https://doi.org/10.1016/j.joms.2005.02.014
  14. Airoldi M, Fornari G, Pedani F et al : Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res 20(5C) : 3781, 2000
  15. Chen CH, Li BY, Wan JT et al : Expression of epidermal growth factor in salivary adenoid cystic carcinoma. Proc Natl Sci Counc Repub China B 25(2) : 90, 2001
  16. O-charoenrat P, Modjtahedi H, Rhys-Evans P et al : Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase-9 in head and neck squamous carcinoma cells. Cancer Res 60 : 1121, 2000
  17. Vered M, Braunstein E, Buchner A : Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 24(7) : 632, 2002 https://doi.org/10.1002/hed.10104
  18. Goldman CK, Kim J, Wong WL et al : Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4 : 121, 1993 https://doi.org/10.1091/mbc.4.1.121
  19. Baker CH, Kedar D, McCarty MF et al : Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 161 : 929, 2002 https://doi.org/10.1016/S0002-9440(10)64253-8
  20. Yigitbasi OG, Younes MN, Doan D et al : Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 64(21) : 7977, 2004 https://doi.org/10.1158/0008-5472.CAN-04-1477
  21. Castilla MA, Neria F, Renedo G et al : Tumor-induced endothelial cell activation: role of vascular endothelial growth factor. Am J Physiol Cell Physiol 286(5) : C1170, 2004
  22. Karja V, Syrjanen S, Kataja V et al : C-erbB-2 oncogene expression in salivary gland tumours. Oral J Otorhinolaryngol Relat Spec 56(4) : 206, 1994 https://doi.org/10.1159/000276657